Νέο φάρμακο για την ψωρίαση
Novartis, Lilly and more look for psoriasis edge with new data at AAD
Προς έγκριση 8 νέες θεραπείες στην Ε.Ε.
7 drugmakers to watch on Q3 earnings
As AbbVie Inc. continues to report Humira growth and investors continue to worry about biosimilar competition, the Chicago-area pharma offered a surprise when it presented its second quarter earnings: a better-than-expected performance for … Continue Reading AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment. Unlike past moves where … Continue Reading Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal